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Characterization of Acyclic Rhodium 
 Tetrathioether Ligand Systems for 105Rh(III) 
Abstract 
 
Rhodium-105 is a 36 hr half-life beta emitter potentially useful for radiotherapy. Previously, the 
reaction of 105Rh-chloride with a linear tetrathioether ligand resulted in several species. 
Evaluation of this reaction at the macroscopic level showed that multiple isomers formed 
depending on the reaction conditions. Radiotracer syntheses for use in potential 
radiopharmaceuticals require formation of a single species. Various reaction conditions were 
examined at the macroscopic level to drive the reaction to a single species, evaluating the effects 
of reducing agent, solvent, temperature, salt concentration, HCl concentration, pH, and reaction 
time. Product distributions were evaluated by LC-MS, NMR, IR, and x-ray crystallography. 
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Chapter 1: Introduction 
Brief History of Nuclear Medicine 
 
Due in large part to extensive research, nuclear medicine has become a staple amongst today’s 
routine medical procedures.[1] As it stands, approximately 95% of all procedures involving a 
radiopharmaceutical are done so with the intent to diagnose an illness, the remaining 
radiopharmaceuticals are intended for therapeutic purposes. At this point it is important to note 
the distinction between nuclear medicine and radiopharmaceuticals; nuclear medicine is a field 
in which radiopharmaceuticals are utilized for diagnostic and/or therapeutic purposes, while a 
radiopharmaceutical is a drug that contains a radioactive atom. 
Nuclear medicine is a compilation of many contributions from scientists all over the world, 
beginning in 1896 with the discovery of radioactivity by Henri Becquerel. Though the discovery 
of radioactivity marked the starting point of endless possibilities for advancement in multiple 
fields, it is arguable that the most significant contribution to nuclear medicine was made by 
Frederic Joliot-Curie and Irene Joliot-Curie in 1934 with the discovery of artificially produced 
radioisotopes. Soon after in December of 1942, began construction on the very first nuclear 
reactor. [1] This meant that man could now produce controlled, self-sustaining nuclear chain 
reactions resulting in relatively large quantities of radioisotopes. The reactor, located in Chicago, 
Illinois, and run by Enrico Fermi et al. at the time, was able to make isotopes commercially 
available for researchers in the medical and biological field.[1] 
At the time, the most utilized radioisotopes for diagnostic and therapeutic purposes were 
phosphorous-32, sodium-24, and iodide-131.[1]  Table 1 displays today’s most utilized 
radioisotopes for diagnostic and therapeutic purposes, along with their intended use for 
specified illnesses. The term “magic bullet,” coined by Nobel Prize winner Dr. Paul Ehrlich, refers 
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to a drug that specifically targets the diseased area while leaving healthy tissues completely 
unaffected.[2]  To date, there is only one true magic bullet, I-131 as a treatment for 
hyperthyroidism and as a cure for metastasized thyroid cancer. Figure 1 displays the decay 
scheme of 131I. 
Though technetium-99m was first isolated from molybdenum-99 in the late 1930s, it was not 
until the mid-1950s that its usefulness in nuclear medicine became apparent. Today it is the 
most widely used radioisotope in the world because its favorable nuclear properties (see Figure 
2) make it advantageous as a diagnostic radionuclide. Technetium-99m is commercially available 
and is shipped to hospitals in a mobile generator that can be eluted for weeks at a time. The 
cost of this isotope is reasonable for the number of uses one can get out of a single mobile 
generator. Figure 2 displays the decay scheme for technetium-99m. 
Table 1 most utilized isotopes for diagnostic and therapeutic purposes, along with their 
intended use for specified illnesses [1][3] 
Isotope Utilization Illness 
89Sr Therapy Bone Cancer 
90Y Therapy Liver Cancer, Non-Hodgkins 
Lymphoma  
131I Therapy Thyroid Cancer, Non-
Hodgkins Lymphoma 
153Sm Therapy Bone Pain Palliation 
99mTc Imaging Thyroid, Liver, Bone, Kidney, 
Cardiac Perfusion, Brain 
18F Imaging Brain, Tumors 
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Figure 1 Decay scheme of 131I. [4] 
       
 
Figure 2 Decay scheme of 99mTc.[5] 
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Introduction to Radiopharmaceuticals 
 
A radiopharmaceutical is considered to be any drug that contains radioactivity. 
Radiopharmaceuticals are used to treat and diagnose diseases via exploitation of a 
radionuclide’s nuclear properties. Characteristics such as half-life, particle and energy emissions, 
and specific activity are significant factors in assessing the viability of a particular isotope as a 
therapeutic or imaging agent.  Other points of consideration necessary in the selection of a 
radionuclide to be used for medicinal purposes include availability and cost. Before a 
radiopharmaceutical can make its way into the clinic, it must be confirmed that the drug is both 
sterile and pyrogen free, thus making the pH, radiochemical and chemical purity pertinent as 
well.[6] 
 The undertaking for the development of a radiopharmaceutical is vast, and thus requires the 
expertise of many. Nuclear medicine is an interdisciplinary field that demands collaboration 
between several branches of chemistry: nuclear, inorganic, organic, analytical, physical and 
medicinal. Other disciplines involved in taking a radiopharmaceutical from concept to clinic 
include physics, veterinary medicine, biology, biochemistry, and medicine.    
Dependent upon the type of illness, the stage of the illness, and what the patient can handle, a 
radiopharmaceutical is introduced into the body either by injection, inhalation, or orally. 
Radiopharmaceuticals are administered in small concentrations (often nM or less), and under 
appropriate safety guidelines so they do not pose a radiation hazard to patients or personnel 
during application of treatment. The goal of nuclear medicine is to treat and/or diagnose a 
patient in a safe, non-invasive, accurate manner.  
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General Concerns that Influence the Design of Radiopharmaceuticals 
 
General concerns when developing a radiopharmaceutical can be broken down into at least 2 
categories: (1) the radionuclide and (2) the pharmaceutical. Considerations that must be 
acknowledged regarding the radionuclide include the following: particle(s) emitted and their 
associated energies, physical half-life, specific activity, radionuclidic purity, and ease of synthesis 
in a clinical setting.[4]  
Radionuclides are unstable nuclei; the lack of stability means that the nucleus emits energetic 
particles in efforts to form a more stable nuclear structure. Radionuclides have been of interest 
in the medical field since radioactivity was discovered in 1896 by Henri Becquerel. The amount 
of energy released, along with its mode of decay, gives each radionuclide its own identifying 
characteristics. Each radionuclide continues to decay until all of its nuclei reach stability. 
Throughout the liberation of energy, there is a change in which the initial radionuclide has 
transitioned into another nuclide, which may or may not be radioactive. This transition is called 
decay. When the initial radionuclide, also known as the parent, decays into a different nuclide of 
lesser energy, known as the daughter, there is a kinetic progression toward the stability of the 
nuclei. It is important to note that in order to reach stability, the parent radionuclide may need 
to undergo several decays. Though the decay process is one of spontaneity, there is 
predictability in how long it will take a radionuclide to decay one-half of its atoms; this 
predictable characteristic is a nuclear property called physical half-life. 
A radionuclide’s physical half-life is of interest because it must be long enough that the 
radiopharmaceutical can be prepared and localized at its targeted site and radiate the affected 
tissue as intended, yet short enough so that the patient does not receive excess radiation dosing 
beyond its target. 
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Specific activity is defined as the amount of activity a radionuclide has per unit mass. If during 
the production process the radionuclide is separated from its target, then the radionuclide is 
said to have high specific activity; if the product cannot be separated from the target, then the 
specific activity is said to be low. In terms of efficacy, a radiopharmaceutical is more attractive 
when it has high specific activity. The lure of having high specific activity comes from the fact 
that less concentration of the radiopharmaceutical is necessary to achieve the same level of 
effectiveness as would be necessary for a low specific activity radiopharmaceutical. 
Consequently, this property dictates the amount of radiopharmaceutical to be administered to 
the patient. 
Radiochemical purity refers to total activity of the desired radionuclide in a chemical or 
biological form.[4]  Impurities can form  during production, through subsequent chemical 
processes, or from storage conditions. This is important to monitor because any impurities 
present may behave differently and undesirably in vivo, possibly causing issues not only with the 
therapy and/or imaging, but also to non-targeted tissues. The standard level of purity for a 
radiopharmaceutical is ≥95%.[4] 
The radiolabelling of a pharmaceutical must be done in a clinical setting or a centralized 
radiopharmacy where product can be shipped in a timely manner if it is to be useful. This can be 
done using kits and generators. An example of a radiopharmaceutical kit is Sestamibi, trade-
named Cardiolite®. Cardiolite® is a radiopharmaceutical used mainly to image the heart muscle 
throughout stress and rest tests. When the kit arrives at a clinic, it is a lyophilized product that 
will need the addition of 99mTcO4-, which is obtained by eluting a 99Mo-99mTc generator.[7] This 
type of innovation makes an onsite nuclear pharmacy possible for hospitals and private 
practices all over the world, however because it is for use in human, rigorous quality control 
checks must be a standard protocol for anyone utilizing these kits. 
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Concerns of the pharmaceutical aspect of a radiopharmaceutical include compatibility, 
stoichiometry, charge of the molecule, size of the molecule, protein binding in vivo, stability, 
solubility, and biodistribution.[7] Before attempting to radiolabel a pharmaceutical it is important 
to ensure that the pharmaceutical has the available functional groups to even do so. It is also 
important to establish biological compatibility (e.g., keeps its structural and functional integrity 
under biological pH, temperature, etc.). 
Synthetic preparation of any drug depends on its stoichiometry, the concentration of each 
component in the formulation. Researchers in pharmaceutical design spend the majority of their 
time working to perfect the formulation of the target drug. When designing a new 
pharmaceutical, this is the starting point. 
Concerns with size and charge are very similar in that they both have an effect on the drug’s 
pharmacokinetics. The term pharmacokinetics refers to the drug’s biological process of 
absorption, distribution, metabolism, and excretion from the body.[8] The rate of diffusion 
expresses the rate at which these processes occur. Most diffusion taking place biologically 
between the drug and the cell is passive, meaning that the cell membrane is permeated by the 
drug. However, if a molecule is too large then its rate of diffusion will be slow, meaning that it 
takes too long for passive diffusion.[8]  The charge of cells in our body is neutral, thus molecules 
with a charge tend to slow down the rate of passive diffusion across cell membranes. 
A drug has to have a purpose and thus a destination. Researchers have been experimenting with 
multiple ways to increase binding specificity to tumor sites by introducing different targeting 
vectors to radiopharmaceuticals using peptides and proteins that will target specific receptors in 
vivo. The objective of this method is to accomplish Paul Ehrlich’s “magic bullet,” as previously 
described. One targeting vector of great interest to researchers recently is a peptide called 
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Bombesin, which targets the gastrin releasing hormone peptide (GRP) receptors highly 
expressed on the cell surface of the following cancer cell lines: bronchial, gastrointestinal, and 
intestinal carcinoids, neuroblastomas, glioblastomas, renal cells, ovarian, uterine, head/neck, 
colon, pancreatic, breast, prostate, and lung.[9]  
It is very important that the drug prescribed by the physician not unexpectedly decompose due 
to biological conditions; this criteria refers to the drug’s stability. If a drug begins to decompose 
once introduced into the body, then it will not function as intended and may cause significant 
damage to the biological system. In efforts to prevent possible decomposition or transition into 
another form, experimentation under biological conditions on the microscopic and macroscopic 
scales are done to ensure the structural integrity of the drug under such conditions. 
Because phospholipids make up the exterior of the cell membrane, a radiopharmaceutical that 
is intended to cross the cell membrane must be lipid soluble or it will not be able to diffuse 
through the cell membrane. This property affects the radiopharmaceutical’s biodistribution. 
Biodistribution studies give important insight into a drug’s function and effectiveness. The first 
set of biodistribution studies are usually done in mice. The four main objectives of a 
biodistribution study are to determine the drug’s pathway once introduced into the body, its 
accumulation in tissues, its pathway out of the body, and the biological half-life of the drug. 
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Brief Overview of Diagnostics and their Complementary Radiopharmaceuticals 
 
Preferred characteristics and properties of radiopharmaceuticals for diagnostic purposes include 
a radioactive component that is commercially available at a reasonable cost, a half-life 
approximately 1 ½ times the length of the procedure, and emission of gamma rays between 80 
keV and 300 keV or annihilation photons at an energy of 511 keV.[8]  Parallel to the development 
of radiopharmaceuticals for diagnostics is the development of instrumentation for imaging. The 
ability to image a patient on the molecular level means that patients undergo a more accurate 
and thus more effective treatment in a non-invasive, painless manner. Nuclear diagnostics also 
provide for the ability to follow a patient’s physiological response to whatever therapy he or she 
is receiving. Currently, radiopharmaceuticals have made it so that patients can be routinely 
screened, increasing the chances of diagnosing ailment(s) in their early stages. Radiologists 
today utilize specialized equipment that allows them the ability to image a patient’s bone, soft 
tissue, blood flow, and/or organs using cameras and detectors that take on different angles 
about the patient to gain 3D images. There are several options that researchers and physicians 
have in regards to imaging instrumentation, however the most used is computed tomography 
(CT). Computed tomography is a strategic way to take 2D images and turn them into 3D by way 
of stacking the 2D on top of each other in a computerized image. Once the radiopharmaceutical 
has been injected into the patient and has had ample time to localize, the detectors can begin 
picking up the emitted photons, gamma and/or X-rays. Once the detectors have captured 
enough of the nuclear events throughout the decay process, the computer can begin creating 
2D images. Once the 2D images have been collected by the computer, the stacking begins and 
the computer transforms those images into layers, creating the 3D image that physicians and 
researchers find useful. This is done by changing the angle of both the camera and detector by 
rotation about the patient or animal being imaged.  Within this category are the imaging 
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modalities single photon emission tomography (SPECT) and positron emission tomography 
(PET), the 2 most widely used nuclear methods of imaging.[11] Each one of these instruments is 
similar in that they detect photons. 
The main use of positron emission tomography is to evaluate the structure, function, and 
biochemical properties such as the metabolism of a particular organ and/or tissue.[12] This form 
of imaging allows for diagnosing a patient before structural changes occur.  When a patient is 
prescribed a PET scan, they will first be injected with an appropriate radiopharmaceutical. Next, 
the radiopharmaceutical will localize in the organ and/or tissue of interest. Throughout this 
process, nuclear events called positron annihilation will take place. During this event, a positron 
will interact with an electron and annihilate, giving off 2 gamma rays of 511 keV each at 180° to 
each other. Cameras positioned 180° apart will pick up these events and build a 3D image with 
them. The biggest advantage of PET is its ability to record a high percentage of the events, 
making it a highly sensitive tool for physicians and researchers.[11] Another important advantage 
of PET lies in how accommodating it is with regard to short lived-radionuclides. Because of the 
high level of sensitivity that PET has, it is able to generate sufficient images in fewer scans. 
Because PET is effective with fewer scans, it is useful for short lived radionuclides, advantageous 
for researchers and physicians. [11] Table 3 shows some of the PET radionuclides, along with 
examples of radiopharmaceuticals in which they are utilized, and pertinent nuclear data. 
The SPECT instrument provides physicians the ability to image blood flow to organs and/or 
tissues.[11] Radionuclides that are used for this particular instrumentation include 123I, 111In, and 
99mTc. Table 1 shows specific examples to which these radionuclides are utilized as 
radiopharmaceuticals. These radionuclides are useful because of their particle and energy 
emissions, also seen in Table 2. As with PET, when a patient is prescribed a SPECT procedure, 
they are given a radiopharmaceutical specific to their needs, that radiopharmaceutical will 
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localize, and nuclear events that take place in the body will be noted by detectors and an image 
generated.[14] SPECT is especially useful in myocardial perfusion testing and brain imaging, due 
to its ability to image complex geometries and structures where 3D imaging is necessary.[6] Some 
disadvantages of SPECT are that it is time consuming and inefficient. However, where heart and 
brain imaging are necessary, the benefits outweigh those disadvantages. To date, molecular 
imaging has become a requisite for physicians and their patients in regards to diagnosing, 
staging, and tracking treatment progress. 
Table 2 Examples of Radionuclides that Complement SPECT[18][11] 
Radionuclide Examples of 
Radiopharmaceutical 
Detectable Source 
Emitted 
Energy Emitted 
by Detectable 
Source 
123I Iodine-123-
Metaiodobenzylguanidine  
(I23I-MIBG) 
γ 159 keV 
111In Indium-111- 
Diethylenetriamine 
pentaacetate 
(111In-DTPA) 
γ 245 keV 
99mTc Technetium-99m- 
Diethylenetriamine 
pentaacetate 
(99mTc-DTPA) 
γ 140.5 keV 
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Table 3 Examples of Radionuclides that Complement PET[8][13] 
Radionuclide Examples of 
Radiopharmaceutical 
Detectable Source 
Emitted 
Energy Emitted 
by Detectable 
Source 
18F 18F-Fluorodeoxyglucose 
(18FDG) 
Annihilation 
Photons 
0.635 MeV 
18F L-3,4-dihydroxy-6-
[18F]fluoro-phenylalanine 
(18F-FDOPA) 
Annihilation 
Photons 
0.635 MeV 
11C 11C-Metomidate 
(11C-MTO) 
Annihilation 
Photons 
0.960 MeV 
64Cu 64Cu-diacetyl-bis(N4-
methylthiosemicarbazone) 
64Cu-ATSM 
Annihilation 
Photons 
0.655 MeV 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
13 
Radiopharmaceuticals for Therapeutic Purposes 
 
Similar to radiopharmaceuticals for diagnostic agents, the radioactive component of a 
therapeutic agent must be commercially available and at a reasonable price.  However, 
preferred nuclear properties for therapeutic agents differ in that typically, particle emissions 
utilized in radiotherapy include alphas (α), beta minus (β-), and/or Auger electrons. 
Requirements for physical and biological half-life, range travelled, and liberated energy are also 
different from those in diagnostics, and vary depending on the procedure, stage of the illness, 
severity of illness, and what the patient can and is willing to handle. The strategy of 
radiopharmaceuticals is to incorporate radionuclides into modes that provide selective uptake  
into cancer and/or tumor cells relative to healthy cells. Currently on the market are therapeutic 
radiopharmaceuticals that come in different forms, yet the goal is the same, to treat cancer 
and/or tumors by accumulating in or near the surface of the cells and/or tumors. The different 
forms include, but are not limited to, surgically implanted sealed source radiation known as 
brachytherapy, ligands that are bifunctional in that they secure both a radionuclide and a 
targeting vector (BFCA) and are injected intravenously, and microspheres made of either glass or 
plastic that are injected into the arteries (See Table 4 for specific examples).[3][15]-[20] Currently, of 
great interest is another mode of therapy called nanoparticles. Nanoparticles can be 
administered radioactive or non-radioactive, and can be injected intravenously or 
intratumorally.[16] Table 4 shows examples of some of the radiotherapeutics either on the 
market today or being studied by researchers because they show promise, along with pertinent 
nuclear data and the capacity for which they are or could be utilized. 
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Radio-
nuclide 
Half-Life 
Therapeutic 
Particle 
Emitted 
Energy 
Emitted 
Radio-
pharmaceutical 
Status of Radio-
pharmaceutical 
Mode Illness 
103Pd 16.99days x-ray 23keV IsoAid Advantage™ Market Brachytherapy 
Prostate, Eye, Breast 
Cancers 
105Rh 35.5hrs β- 566keV 105Rh-S4-BBN(7-14) 
Research: 
Cell Lines and 
Mouse Models 
BFCA 
(injected 
intravenously) 
Lung, prostate, breast, 
pancreatic, head/neck, 
colon, uterine, ovarian, 
renal cell, gastrointestinal 
carcinoids, intestinal 
carcinoids, bronchial 
carcinoids, glioblastomas, 
and neuroblastomas. 
90Y 2.67days β- 2.28MeV TheraSphere® Market Microspheres Liver Cancer 
198Au 2.69days β- 961keV GA-198AuNP 
Research: 
Mouse Models 
Nanoparticles Prostate Cancer 
153Sm 46.9hrs β- 690keV Quadramet® Market 
Chelate 
EDTMP 
 
Bone Palliative 
1
4
 
Table 4    Examples of some of the radiotherapeutics either on the market today or being studied by researchers because they show promise 
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Chapter 2: Previous Work 
Previous Work 
 
A bifunctional chelating agent (BFCA) is a ligand with the ability to sequester a metal while also 
possessing a chemically reactive functional group where a biological component can be 
conjugated (i.e., antibody fragments, mAbs, peptides, etc.). The current work is an extension of 
a project that originated in 1996 when Goswami et. al., described why tetrathioether ligands 
were of interest as potential bifunctional chelating agents.[24] Goswami et. al., later published a 
paper on biological evaluations of multiple tetrathioether ligands complexed with 105Rh, and the 
results suggested that the 105Rh-3,3,3-S4-AcOH ([105RhS4Cl2(COOH)2]⁺)(see Figure 3) complex 
could be a viable option as a radiotherapeutic agent due to the bifunctionality  of the chelate, 
hydrophilicity added by the presence of the pendent carboxylic acid, biological evaluation 
studies, and nuclear characteristics of 105Rh.[27] At this point it is important to note that Goswami 
et. al., did not have HPLC or LC-MS to aid in characterization of the [105RhS4Cl2(COOH)2]⁺ 
complex. His proton NMR was difficult to interpret, however his carbon NMR suggested that 1 
species had been synthesized. Because no further characterization had been done, whether or 
not a single species was obtained cannot be answered definitively. In 2012, the project 
progressed in the hands of Carroll et. al. The aim of her work was to synthesize a novel 
radiotherapeutic for prostate cancer by conjugating [105RhCl2(S4(COOH)2)]⁺ with targeting vector 
bombesin (BBN(7-14)) (see Figure 3), a peptide that will be discussed later in this writing.[21] 
While attempting to synthesize the [RhCl2-S4-8Aoc-BBN(7-14)NH2]+ complex, Carroll et. al., 
discovered, through HPLC, LC-MS, and M.S., that she had a mixture of Rh(III)S4 species, notably 
[RhCl2-S4-8Aoc-BBN(7-14)NH2]+ and [RhCl-S4-8Aoc-BBN(7-14)NH2]+ (see Figures 4 and 5), 
however in low yields.  The reason for this is hypothesized to be the way in which the 
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rhodium(III) reacted with the S4 ligand during the reducing step. The use of ethanol as the 
reducing agent proved problematic because it resulted in either one or both free acids either 
becoming coordinated carboxylates or esterified, and thus a mixture of several different Rh(III)S4 
products.[21] Figure 6 shows the different Rh(III)S4 species that were made while attempting to 
synthesize  105RhCl2(S4(COOH)2)]⁺. It is clear that the reducing agent, ethanol (C2H6O), is 
influencing the chemistry of the free acids by displacement, which is why current work utilizes a 
different reducing agent. 
Figure 3 [105RhS4(COOH)2]⁺  
 
 
Figure 4 Target molecule from Previous Work [RhCl2-S4-8Aoc-BBN(7-14)NH2]+ 
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Figure 5  Molecule from previous work [RhCl-S4-8Aoc-BBN(7-14)NH2]+ 
 
 
 
Figure 6 Displays the Rh(III)S4 products made when ethanol is used as the reducing agent 
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Objective 
 
The main objective of this work is to drive synthesis to a single Rh(III)S4 species and isolate it in 
high enough yields to characterize. This is an important step because the desired complex will 
be synthesized on the tracer scale, and identification of all products made must be confirmed.  
In doing so, we will be better able to move forward with the [105RhS4Cl2(COOH)2]-BBN(7-14) 
project that began in 2012, thus moving us closer to distinguishing this compound as a possible 
radiopharmaceutical aimed at treating and imaging prostate cancer in humans.[21] 
This chapter aims at explaining why each component (i.e., metal, ligand, and targeting vector) of 
the BFCA was selected.  
 
 
Selection of the S4 Ligand 
 
The term ligand is of Latin origin and means “to bind.”[22] In a coordinated system, one with a 
central atom that acts as an electron receptor, the role of the ligand is to bind tightly to the 
central atom to give a stable complex. The selection of a ligand system for a metal requires 
careful consideration with regard to structure, function, physiological compatibility, and overall 
application. Ligand design has become a powerful tool in nuclear medicine, which justifies its 
continuing interest amongst researchers.  
For this project, the structure of the ligand includes 4 thioether sulfurs, which act as electron 
donors. Rh(III) from RhCl3·3H2O acts as an electron acceptor, which once reduced to Rh(I) is able 
to complex more readily with the ligand.[24] The Rh(I) then re-oxidizes to Rh(III), which is 
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kinetically inert. The interaction between the S4 ligand atoms and the metal center 
demonstrates the chelate effect; the propensity for increased interaction between a multi-
dentate ligand and metal ion leads to increased stability.[23] Analysis of periodic trends shows 
that group VIIIB metals, which includes rhodium, are among the most reactive with regard to 
sulfur ligation.[23] Under reducing conditions, the sulfur-donor complexes with the rhodium 
metal. This reaction is encouraged by the overlapping of the pi-orbitals between the sulfurs and 
Rh(III) (p𝜋 → 𝑑𝜋).[24] The dicarboxylic acid substituted, open chain, acyclic, tetrathioether ligand 
system was selected in efforts to both optimize the chelate effect and utilize the dicarboxylic 
acids’ ability to covalently link to targeting vectors. 
It is known that this particular complex, [105RhCl2(S4(COOH)2]+, shows favorable results in normal 
mice in regards to physiological compatibility (see Table 3 for biodistribution study results.)[24] 
Results showed that the vast majority of the complex excreted through the urine at 0.25 hours, 
1 hour, and 2 hours. It is for these reasons (e.g., bifunctionality, stability, and biocompatibility) 
that the S4 ligand was selected as the BFCA for this potential radiopharmaceutical. 
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Table 3 Results from biodistribution studies involving complex [105RhCl2(S4(COOH))2]+  in nude mice 
conducted at the University of Missouri-Columbia in1996. The vast majority of the clearance occurs through 
the urine.[24] 
 
Rhodium-105 Radiochemistry 
 
As early as 1988, 105Rh was of interest to researchers looking at potential ways to treat prostate 
cancer.[25] Due to its desirable nuclear and chemical properties, it has been proposed that 105Rh 
is a suitable isotope for use as a therapeutic radionuclide.[19][25][26] Rhodium-105, a beta emitting 
radionuclide (0.560 MeV [70%], 0.250 MeV [30%]) with a 36 hr half-life, also emits gamma rays 
(306 keV) [5%], 319 keV [19%]), which can also be useful for in vivo tracking of the therapeutic 
dose.[27] Its moderate βˉ energy has a maximum range in water of 1.9 mm, which can be useful 
for irradiation of medium sized tumors.[27] The 36 hr half-life is convenient because it would 
allow enough time for shipping, labeling, and in vivo localization.[27] In addition to its favorable 
nuclear properties, it is available from reactors as a non-carrier-added (NCA) product, yielding 
high specific activity. It is produced from 104Ru by neutron capture to form 105Ru, which then 
0.25h 1h 2h
Brain 0.09±0.07 0.03±0.03 0.03±0.02
Blood 4.01±0.71 0.94±0.18 0.65±0.25
Heart 0.06±0.04 0.05±0.03 0.02±0.01
Lung 0.25±0.11 0.08±0.03 0.04±0.02
Liver 9.91±0.84 7.86±0.96 6.37±0.43
Spleen 0.08±0.05 0.05±0.07 0.00±0.00
Intestines 9.50±2.48 14.26±2.43 12.52±1.14
Kidneys 3.96±0.29 2.39±0.19 2.24±0.21
Urine 53.65±3.42 69.99±1.99 73.89±1.83
Muscle 0.07±0.06 0.03±0.05 0.02±0.04
Pancreas 0.20±0.01 0.06±0.05 0.05±0.03
Biodistribution of 105RhCl2[S4(COOH)2]+ Complex in Normal Mice
% Injected Dose per Organ
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beta decays with a half-life of 4.4 hrs to 105Rh.[19] The chemistry of rhodium(III) is favorable due 
to its low spin, d6 configuration, making it very kinetically inert, a factor that is of great 
importance in vivo, as it discourages substitution. 
 
Targeting Vectors: Introduction to Bombesin 
 
Radiolabeled, receptor specific peptides as targeting vectors for therapeutic and/ or diagnostic 
radiopharmaceuticals have become increasingly popular.[28] The fact that tumor cells have 
overexpressed receptors on the surface of some tumors makes in vivo targeting an ideal method 
for treating certain cancers. Previously, the bombesin peptide(BBN(7-14))  had been selected as 
the targeting vector for the 105RhClS4(COO)-BBN(7-14)) molecule and evaluated in a competitive 
binding displacement assay using a PC-3 cell line.[21] Results showed that the 105RhClS4(COO)-
BBN(7-14)) molecule had a high affinity for the BBN receptors expressed on the PC-3 Cell line. 
The PC-3 cell line is specific for prostate cancer and is a useful tool in helping researchers 
conduct in vitro studies with potential chemotherapeutics. Isolated in a lab for the first time in 
1971, by researchers at the Milan Institute of Medical Pharmacology, University of Rome, Italy, 
BBN is an analog of mammalian gastrin-releasing peptide (GRP) that is found naturally in the 
skin of the European fire-bellied toad.[29] Bombesin is a 14 amino acid long peptide that has 
been shown in mice to have high binding affinity towards gastrin-releasing peptide receptors 
(GRP-R) ; BBN is useful in targeting over expressed GRP-R on the surface of tumors of the breast, 
prostate, small cell lung, pancreas, and gastrointestinal stromal.[30] 
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Chapter 3: Experimental 
 
Materials 
 
Rhodium trichloride (trihydride) was obtained from Alfa Aesar. All other chemicals were 
purchased from Aldrich Chemical Company, Acros Organics, Fisher Scientific or Tokyo Chemical 
Industry Company (TCI), were of reagent grade, and used as received unless otherwise specified. 
Silica gel was obtained from Acros Organics, 0.060-0.200mm, 60Å. Glass column for 
chromatography; dimensions ~20 cm in length, ~4.5 cm in width, ~2.25 cm in radius.  
 
Physical Measurements and Instrumentation 
 
1H- and 13C-NMR spectra were obtained in CDCl3, CD3CN, D2O, or DMSO on either a Bruker ARX-
300, 500, or 600 MHz spectrometer. IR spectra were obtained by a Thermo Scientific Auxiliary 
Equipment Module (AEM) for Nicolet FT-IR spectrometers. Liquid chromatography-electrospray 
ionization-mass spectroscopy (LC-ESI-MS) analysis and semi-preparative RP-HPLC were carried 
out on a Beckmann Coulter (Fullerton, CA) System Gold HPLC equipped with the 32 KARAT 
software package, a 507e auto-injector and a 168 diode array detector coupled to a Thermo 
Scientific (Waltham, MA) LTQ XL ion trap mass spectrometer. 
X-ray Structure Determinations and Refinements for (3) and (5). Intensity data were obtained at 
-100°C on a Bruker SMART CCD Area Detector system using the ω scan techniques with Mo Kα 
radiation from a graphite monochromator. Intensities were corrected for Lorentz and 
polarization effects. Equivalent reflections were merged, and absorption corrections were made 
using the multi-scan method. The structure was solved by direct methods with full-matrix least-
squares refinement, using the SHELX package.[31][32] All non-hydrogen atoms were refined with 
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anisotropic thermal parameters. The hydrogen atoms were placed at calculated positions and 
included in the refinement using a riding model, with fixed isotropic U. The final difference map 
contained no features of chemical significance. Space group, lattice parameters and other 
relevant information for (3) and (5) along with the data are given in Appendix 3. 
 
Synthesis of S4 Ligand 
 
 
 
Summary of S4 synthesis:  2,6,10,14- Tetratiapentadecane-1,15- Dicarboxylic Acid, 
HOOCCH2S(CH2)3S(CH2)3S(CH2)3SCH2COOH, 333-S4-diAcOH[33] 
Scheme 1 Intermediate 1 (1) 
              4 mL   40 mL           6.6 mL 
          45 mmol            420 mmol         47 mmol 
 
 
 
Synthesis of S4 Intermediate 1: 6-Chloro-3-Thiahexylacetate, CH3OC(O)CH2S(CH2)3Cl: 
4.0 mL of methylthioglycolate (4.5 g, 45 mmol), 40 mL of 1,3-dichloropropane (46.5 g, 420 
mmol), and 6.6 mL of dry triethylamine (4.74 g, 47 mmol) were added to a round bottom flask 
and gently refluxed under nitrogen in an oil bath at about 84°C for approximately  4 hours. The 
mixture was cooled, the precipitated triethylamine hydrochloride salt removed by filtration, and 
the excess 1,3-dichloropropane removed under vacuum at 60°C. Approximately 5.2 mL of a 
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yellow oil was obtained; an 80% yield. The oil was purified by silica-gel column chromatography 
with a dry mass of silica gel to sample ratio of about 80:1. A 3:1 hexanes to diethylether mixture 
was used as the mobile phase as well as to apply the oil to the column. The fractions containing 
intermediate 1 as shown by TLC and NMR were combined and the mobile phase removed under 
vacuum at 45°C. The product was then dried on a Schlenk line overnight. Approximately 71% of 
the oil applied to the column was recovered as the purified intermediate 1 (87% yield). The oil 
had a slight yellow color.  
 
NMR 
1H NMR (300 MHz, CDCl3): δ ppm: 3.74 (s, -O-CH3, 3H), 3.64 (t, -S-CH2-CO-, 2H), 3.23 (s, -C-CH2-O-
, 2H), 2.79    (t, -S-CH2-CO-, 2H), 2.06 (p, CH2-CH2-CH2, 2H). The singlet at 3.74 ppm represents 
the 3 protons of the methoxy. The triplet at 3.64 represents 2 protons from a methylene group 
located between a sulfur and a carbonyl group, which lies between the expected ranges of 3.1-
4.2 ppm.[34] The singlet at 3.23 ppm represents 2 protons from the methylene group that lies 
between another methylene group and a Chloride. It is the chloride that shifts the signal 
downfield. The triplet at 3.79 ppm represents 2 protons on a methylene group that lie between 
a sulfur and another methylene. The pentet at 2.05 ppm represents 2 protons on a methylene 
that is split between 2 other methylene groups, explaining the splitting pattern.  
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Silica gel TLC plates, mobile phase of 3:1 hexanes-diethyl ether                                                                         
Rf values: 0.00, 0.07, 0.35, 0.56, 0.70, 0.96. The desired product is at 0.56. 
   
 
   
 
            
            
             
 
 
Synthesis of S4 Intermediate 2: 2,6,10,14- Tetrathiapentadecane- 1,15- Diacetate, 
CH3OC(O)CH2S(CH2)3S(CH2)3S(CH2)3SCH2C(O)OCH3[33] 
Scheme 2 Intermediate 2 (2) 
                    3.2 mL               0.96 mL              2.8 mL 
  19.6 mmol                     9.6 mmol                      20 mmol 
 
 
Intermediate 1 (3.58 g, 19.6 mmol) and 2.8 mL of dry triethylamine (2.0 g, 20 mmol) were 
combined in a round bottom flask. 0.96 mL of 1,3-propanedithiol ( 1.00 g, 9.6 mmol) was added 
dropwise to the reaction mixture over 1 minute. The mixture was heated on an oil bath at about 
96°C and refluxed for approximately 24 hours. The mixture was cooled and slurried with diethyl 
ether. The precipitated triethylamine hydrochloride salt was removed by filtration. The diethyl 
  
 
 
26 
ether was removed under vacuum at about 40°C. The intermediate 2 oil product of nearly 3 mL 
in volume was diluted in hexanes and diethyl ether, 3:1, to a volume of about 10 mL and added 
to a silica-gel column (~20cm in length, ~4.5cm in width, ~2.25cm in radius) prepared in 3:1 
hexanes: diethyl ether. The product fractions were eluted with the hexanes and diethyl ether 
3:1 mobile phase. Those fractions containing intermediate 2, as shown by silica gel TLC as having 
an Rf value of 0.56 were combined and the mobile phase removed by rotary evaporation at 
approximately 40°C, then dried on a Schlenk line overnight. A total of 2.35 g (5.88 mmol) of 
intermediate 2 was recovered for a yield of 60% based on the amount of intermediate 1 used.  
 
NMR 
1H NMR (500 MHz, CDCl3): δ ppm: 3.65 (s, -O-CH3, 6H), 3.15 (s, -C-CH2-O-, 4H), 2.66 (t, -CH2-S-
CH2-CO-, 4H), 2.53(t, -CH2-CH2-S-CH2-CH2- 8H), 1.79 (m, -CH2-CH2-CH2, 6H). This molecule has 
multiple points of equivalency, as it is symmetrical about the y-axis. The peak at 3.65 ppm is lies 
between ranges 3.9-3.5 ppm, a position characteristic of free methoxy groups adjacent to a 
carbonyl group.[34] This singlet represents 6 protons. The methylene group between the sulfur 
and carbonyl group is representative of 4 protons. Its 3.15 ppm shift is within the 3.1-4.1 ppm 
range of a methylene group between a sulfur and a carbonyl group.[34] The triplet at 2.66 ppm is 
a methylene group that represents 4 protons and lies between a sulfur and another methylene 
group. The triplet at 2.53 ppm represents 8 methylene protons split between sulfur and other 
methylene groups. The multipplet at 1.79 ppm represents 6 protons, all from methylene groups 
split between two other methylene groups.   
13C NMR (500 MHz, CDCl3): δ ppm: 170.80 (C=O), 52.37 (-OCH3), 33.39 (-CO-CH2-S-), 31.47 (-S -
CH2-CH2-), 30.75 (-CH2-CH2-S-), 29.21 (CH2-CH2-CH2-), 28.62 (CH2-CH2-CH2-). The signal at 170.80 
ppm represents 2 carbons and is within the range characteristic of carbonyl carbons.[34] The shift 
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at 52.37 ppm is assigned to the carbon of the methoxy groups, as methoxy group carbons are 
expected around 52 ppm.[32] This peak represents 2 carbons. The peak at 33.39 ppm represents 
2 carbons and lies between a carbonyl group and a sulfur. The peak at 31.47 ppm represents 2 
carbons and is assigned to the carbon of a methylene group that lies between sulfur and 
another methylene group. The chemical shift at 30.75 ppm represents 3 carbons and is the 
carbon of a methylene group split between 2 other methylene groups. The peak at 29.21 ppm 
represents 2 carbons and is the carbon of a methylene group split between a methylene group 
and a sulfur. The peak at 28.62 ppm represents 2 carbons and is assigned to a methylene group 
split between a sulfur and another methylene group.   
 
Silica gel TLC plates, mobile phase of 3:1 hexanes-diethyl ether                                                            
Rf values: 0.02, 0.14, 0.27, 0.54, 0.74. The desired product is at 0.74. 
   
 
   
 
            
            
            
            
         
   
 
 
 
 
 
 
 
  
 
 
28 
 
Synthesis of 2,6,10,14- Tetrathiapentadecane- 1,15- Diacarboxylic Acid, 
HOOCCH2S(CH2)3S(CH2)3S(CH2)3SCH2COOH, final product, 333-S4-diAcOh, S4[33] 
Scheme 3 S4 (4) 
 
 
Intermediate 2 (2.046 g, 5.1 mmol) was transferred to a round bottom flask. An alkaline solution 
of methanol (1.194 g KOH 88%, 18.8 mmol hydroxide in 6 mL of methanol) was added to the 
round bottom flask. A stir bar was added and the flask heated in an oil bath at about 55°C. Upon 
completion of the reaction the solid potassium salt of the S4 product was filtered, washed with 
a little methanol and then dissolved in about 10 mL of water. 6N HCl was added dropwise to the 
aqueous solution until the formation of the thick white precipitate was complete at about pH 2. 
The precipitate was filtered and dried under vacuum overnight.  Approximately 1.348g of S4 
product was collected for a yield of 71%.  
NMR 
1H NMR (500 MHz, CD3CN, D2O): δ ppm: 3.27 (s, -S-CH2-COOH, 4H), 2.69 (t, -CH2-CH2-S-, 4H), 2.60 
(t, -CH2-CH2-S-CH2-CH2- 8H), 1.81 (m, -CH2-CH2-CH2, 6H). This molecule is symmetrical about the 
y-axis. The single peak at 3.27 falls within the expected range of 3.1-4.2 ppm for a methylene 
group between a carbonyl group and a sulfur.[34] This peak represents a total of 4 protons. The 
triplet at 2.69 ppm represents 4 protons and is a methylene split between a sulfur and another 
methylene group. The triplet at 2.60 represents 8 protons. This triplet is a methylene split 
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between a sulfur and another methylene group. The pentet at 1.81 represents 6 protons and is 
a methylene group split by 2 other methylene groups, explaining its splitting pattern. The lack of 
a peak for the carboxylic acid proton is due to the fact that D2O was used as part of the solvent 
system, and the protons rapidly interchange. However, confirmation of this functional group can 
be seen in the 13C NMR spectra. 
13C NMR (500 MHz, CD3CN, D2O): δ ppm: 172.06 (-COOH), 33.20 (-CO-CH2-S-), 30.89                      
(-S-CH2-CH2-), 30.00 (-CH2-CH2-CH2-), 29.19 (-CH2-CH2-S-), 28.64 (-S-CH2-CH2-). The peak at 172.06 
lies within the ranges 160-185 ppm, characteristic of the carbon on a carboxylic acid.[34] This 
peak represents 2 carbons. The peak at 33.20 ppm is assigned to the carbon of the methylene 
that lies between a carbonyl group and sulfur. This peak represents 2 carbons. The peak at 30.89 
ppm represents 2 carbons. This peak is the carbon of a methylene group and lies between sulfur 
and another methylene group. The doublet at 30.00 ppm represents 3 methylene carbons and is 
split between 2 other methylene groups, which may explain the splitting pattern. The peak at 
29.19 ppm is a methylene that lies between another methylene group and sulfur. This peak 
represents 2 carbons. The peak at 28.64 represents 2 carbons and lies between a methylene 
group and a sulfur.  
Silica gel TLC, mobile phase of acetonitrile   
Rf values: The desired product is at 0.67. 
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Synthesis for trans-[RhCl2S4(COOCH3)2]PF6 (3) 
 
 
A 100 mL round bottom flask was loaded with 28mL of water and 0.44 mL 1.21 M HCl. To this 
was added a solution of RhCl3•3H2O (40 mg, 0.15 mmol) in ACN (2 mL). Drop wise, a solution of 
SnCl2 (60 mg, 0.32 mmol) in water (1 mL) was added. The reaction mixture was heated at 45 °C 
while allowed to stir for 10 min to afford a homogenous orange solution. After 10 min, a 
solution of (2) (50 µL, 0.16 mmol) ACN (0.25 mL) was added drop wise. The solution was allowed 
to stir in the oil bath at 45°C for 45 min and then taken out and placed in an ice water bath for 
10 min. The solution was then centrifuged, decanted, and the supernatant kept. Rotary 
evaporation to ~2 mL in volume was to follow. The addition of NH4PF6 (aq) presented an orange 
precipitate. The solution was placed in an ice water bath to ensure maximum precipitation, then 
centrifuged and the pellet kept. The pellet was dissolved in a minimum amount of CHCl3 and 
CH2Cl2 (1 : 1). The solution was then passed through Na2SO4. The solution was collected into a 20 
mL scintillation vial where yellow-orange single crystals of X-ray diffraction quality accumulated 
within 24 hrs under ambient conditions. Forty-six milligrams of product was collected for a yield 
of 53%. 
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Scheme 4 trans-[RhCl2S4(COOCH3)2]PF6 (3)  
 
 
 
 
NMR 
1H NMR (500 MHz, CD3CN, δ): 3.78 (s, 6H), 3.74-3.61 (m, 2H), 3.39-2.96 (m, 8H), 2.94-2.75 
(m, 4H), 2.74-2.37 (m, 6H), 2.36-2.12 (m, 2H). With this data it is difficult to make an absolute 
assignment of most signals, however the singlet at 3.78ppm arises from 6 protons and is assigned 
to the methyl protons of the double methoxy. 
 13C NMR (500MHz, CD3CN): δ 166.57 (C=O), 52.97 (-OCH3), 35.70 (-S-C-C-), 35.35 (-CH2-
CH2-S), 32.69 (-CH2-CH2-S-), 29.85 (CH2-CH2-CH2-), 22.20 (CH2-CH2-CH2-). The signal at 
166.57 ppm is assigned to the carbonyl carbon of the ester. The chemical shift is expected of the 
carbonyl group, especially for esters. The shift at 52.97 ppm is assigned to the carbon of the 
methoxy groups, as methoxy group carbons are expected around 52 ppm. IR (KBr): 2900 cm-1, 
1740 cm-1, 1400 cm-1, 1300 cm-1, 1200 cm-1, 810 cm-1, 570 cm-1. The double peak signal at 
2900cm-1 is indicative of the methoxy group. The strong signal at 1740 cm-1 is the carbonyl 
carbon, which is to be expected because it is generally where the carbonyl stretch appears. The 
mid-range stretches between 1200 cm-1 and 1400 cm-1 are most likely indicative of the multiple –
CH2- groups that this complex possesses. The very strong stretch to the baseline at 810 cm-1 is 
characteristic of the PF6 counter ion. The strong stretch at 580 cm-1 is in the thioether region. X-
ray crystallography: Yellow-orange crystals of (3) were obtained as described and were stable to 
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air during the analysis for months afterward. Details of the X-ray structure experiments are given 
in Appendix 2. Figure 7 shows the ORTEP diagram of (3). 
 
  
Figure 7 ORTEP representation of trans-[RhCl2S4(COOCH3)2]PF6 (3), with 50% thermal 
ellipsoids. Hydrogen atoms have been omitted for clarity, as well as the PF6 counter ion; color 
key: red = O, blue = Rh, gray = C, yellow = S, green = Cl. 
 
 
 
 
Synthesis for trans-[RhCl2S4(COOH)2]+ (5) 
 
A 100 mL round bottom flask was heated on an oil bath at 65°C then loaded with 50 mL of 
acetonitrile. To this was added RhCl3·3H2O (50 mg, 0.19 mmol) and (4) (69 mg, 0.17 mmol). The 
reaction was allowed to stir until its contents were dissolved. Drop wise, a solution of SnCl2 (42.5 
mg, 0.04 mmol) in 0.12µM HCl (500 µL) was added. The mixture was allowed to stir at 65°C for 
2 hrs. The reaction was then taken off the oil bath, filtered, rotary evaporated to dryness and then 
placed on the Schlenk line overnight. Fifty-one milligrams of crude product was collected as a 
crystalline solid (49% yield). To confirm (5) was made, LC-ESI-MS was used. To prepare the 
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sample, ~ 2 mg of the crude product was dissolved in 50 μL of 50:50 solvent A in solvent B (see 
Table 4). To this was added 200 μL of solvent A. The solution was then centrifuged and the 
supernatant injected onto an analytical RH-HPLC 18C column (150Å, 0.46 cm x 15 cm x 5 μm) 
at a flow rate of 1 mL/min, and UV detection at 280 nm. A linear gradient of solvent B in A (10% 
B→20% B over 25 min) was used. Results showed the expected molecular mass of ~545 within 3 
different peaks at Tr1= 5.76 min, Tr2= 7.71 min, and Tr3= 12.21 min. This sample became the 
standard for the purification step. To purify each peak, the remaining crude product was dissolved 
in 2 mL 50% solvent B in A, then diluted with 8 ml of solvent A. The solution was then 
centrifuged and the supernatant kept and injected onto a semi-preparative RP-HPLC C18 column 
(60 Å, 1.9 cm x 30 cm x 6 μm). A linear gradient of solvent B in A (10% B→30% B over 60 
min) with flow rates up to 10 mL/ min and UV detection at 225 and 280 nm. Three peaks were 
collected at Tr1=5.79 min, Tr2=7.56 min, and Tr3=13.17 min. Once collected, the eluent was 
removed under lyophilization for 24 hrs. Approximately 10 mg of the crude product (between all 
3 peaks) was recovered (20% yield). Data was only collected on peak Tr3= 13.17 because it was 
the most abundant of the 3 peaks (6.1 mg). 
 
Table 4 Solvent system for semi-prep HPLC C18 Column 
Solvent Concentration 
A Water + 0.1% TFA 
B ACN + 0.1% TFA 
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Scheme 5 trans-[RhCl2S4(COOH)2]+ (5)  
 
NMR 
1H NMR (600 MHz, DMSO-d6): δ ppm: 4.01 (d, 2H), 3.94-3.78 (m, 4H), 3.75-3.68 (m, 2H), 3.13 
(m, 4H), 3.05 (s, 6H), 2.94 (s, 4H) . With this data it is difficult to accurately assign peaks. This 
data does however show broad peaks in the aliphatic region, where we expect our peaks to be 
present.  
13C NMR (600MHz, DMSO-d6): δ ppm: 167.78 (-COOH), 36.02 (-CO-CH2-S-), 35.15 (-S-CH2-
CH2-), 32.22 (-CH2-CH2-S-), 29.72 (-S-CH2-CH2-) 21.78 (-CH2-CH2-CH2-). The peak at 167.78 
lies within the ranges 160-185 ppm, characteristic of the carbon on a carboxylic acid.[34] This 
peak represents 2 carbons. The peak at 36.02 ppm is assigned to the carbon of the methylene that 
lies between a carbonyl group and sulfur. This peak represents 2 carbons. The peak at 35.15 ppm 
represents 2 carbons. This peak is the carbon of a methylene group and lies between sulfur and 
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another methylene group. The peak at 32.22 ppm is a methylene that lies between another 
methylene group and sulfur. This peak represents 2 carbons. The peak at 29.72 represents 2 
carbons and lies between a methylene group and a sulfur. The split peaks at 21.78 ppm represents 
3 methylene carbons and is split between 2 other methylene groups. 
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Chapter 4: Results and Discussion 
 
The use of stannous chloride in place of ethanol as a reducing agent proved useful in limiting the 
number of complexes produced during the chelation step of synthesis. Driving the reaction to a 
single species became less complex when the possibility of esterification was no longer present. 
The use of HPLC and LC-ESI-MS proved extremely useful throughout characterization. The use 
of HPLC allowed for confirmation of a single species. The use of LC-ESI-MS was useful in that 
it confirmed the mass of each species, allowing us to compare expected values with the 
experimental. Also of value from the LC-ESI-MS was the mass to charge ratio that showed the 
characteristic isotropic abundance pattern of having 2 chlorine atoms present in each of the 
isolated molecules.   
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Chapter 5: Conclusion 
 
Although isolation of trans-[105RhCl2S4(COOH)2)]+ appeared successful in 1996, it is now known 
that the synthesized reaction mixture included multiple species that went unobserved by Goswami 
et. al., due to lack of characterization by HPLC and/or LC-ESI-MS. It was Carroll et. al., who did 
those characterization studies and discovered that multiple species were being made in 
conjunction with low yields of the expected molecule (<10%). In 2012 this work began in efforts 
to isolate and characterize single species of Rh(III)S4. 
We have successfully synthesized, isolated and characterized multiple Rh(III)S4 species on the 
macroscopic scale by varying reaction conditions. Species trans-[RhCl2S4(COOCH3)2]+ and 
trans-[RhCl2S4(COOH)2]+ were isolated by changing the original conditions investigated by 
Goswami et. al., and Carroll et. al. The results have yielded species that can now be utilized with 
105Rh and BBN in future studies toward a potential BFCA for a radiotherapeutic. The most 
interesting and useful species of the two, due to the dangling pendent carboxylic acids, is      
trans-[RhCl2S4(COOH)2]+.  
Future studies will most likely focus on how trans-[RhCl2S4(COOH)2]+  on the tracer scale, when 
radioactive and conjugated to BBN (trans-[105RhCl2S4(COOH)-8Aoc-BBN(7-14)NH2]+), will 
behave under physiological conditions. Biodistribution studies, IC50 studies, stability studies, and 
studies with mouse models are recommended.  
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Appendix 2: IR Data 
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Appendix 3: Crystal Structure Data 
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trans-[RhCl2S4(COOCH3)2]PF6 (3): 
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Table 1.  Crystal data and structure refinement for trans-[RhCl2S4(COOCH3)2]PF6. 
Identification code  trans-[RhCl2S4(COOCH3)2]PF6 
Empirical formula  C15 H28 Cl2 F6 O4 P Rh S4 
Formula weight  719.39 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21/n 
Unit cell dimensions a = 13.260(2) Å = 90°. 
 b = 15.375(2) Å = 116.630(2)°. 
 c = 14.210(2) Å  = 90°. 
Volume 2589.8(7) Å3 
Z 4 
Density (calculated) 1.845 Mg/m3 
Absorption coefficient 1.315 mm-1 
F(000) 1448 
Crystal size 0.550 x 0.100 x 0.050 mm3 
Theta range for data collection 1.747 to 27.469°. 
Index ranges -17<=h<=17, -19<=k<=19, -18<=l<=18 
Reflections collected 29805 
Independent reflections 5913 [R(int) = 0.0471] 
Completeness to theta = 25.242° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.94 and 0.78 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5913 / 21 / 355 
Goodness-of-fit on F2 1.049 
Final R indices [I>2sigma(I)] R1 = 0.0300, wR2 = 0.0584 
R indices (all data) R1 = 0.0436, wR2 = 0.0632 
Extinction coefficient n/a 
Largest diff. peak and hole 0.511 and -0.471 e.Å-3 
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 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for trans-[RhCl2S4(COOCH3)2]PF6.  U(eq) is defined as one third of  the trace of the orthogonalized Uij 
tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
Rh(1) 453(1) 520(1) 2754(1) 17(1) 
Cl(1) -829(1) 1279(1) 1266(1) 24(1) 
Cl(2) 1693(1) -249(1) 4255(1) 21(1) 
S(1) 2012(1) 957(1) 2474(1) 22(1) 
S(2) 139(1) -713(1) 1687(1) 19(1) 
S(3) -1003(1) 66(1) 3159(1) 21(1) 
S(4) 759(1) 1857(1) 3668(1) 26(1) 
P(1) 5318(1) -1214(1) 8917(1) 25(1) 
F(1) 4482(8) -1979(7) 8785(6) 40(2) 
F(2) 6210(9) -439(6) 9074(9) 37(2) 
F(3) 6294(6) -1904(4) 9090(10) 55(3) 
F(4) 5751(5) -1187(5) 10155(4) 43(2) 
F(5) 4422(7) -493(6) 8777(6) 43(2) 
F(6) 4957(10) -1205(7) 7705(6) 57(3) 
O(1) 1408(2) 2722(1) 1659(1) 25(1) 
O(2) 848(2) 2426(1) -54(1) 25(1) 
O(3) 3207(2) 1651(1) 4911(2) 37(1) 
O(4) 3186(2) 1211(1) 6420(1) 29(1) 
C(1) 2855(2) 10(2) 2529(2) 25(1) 
C(2) 2281(2) -722(2) 1746(2) 26(1) 
C(3) 1461(2) -1260(2) 1982(2) 23(1) 
C(4) -399(2) -1530(2) 2272(2) 22(1) 
C(5) -1655(2) -1415(2) 1929(2) 27(1) 
C(6) -2016(2) -484(2) 1977(2) 25(1) 
C(7) -1896(2) 976(2) 3117(2) 30(1) 
C(8) -1263(3) 1682(2) 3903(2) 33(1) 
C(9) -568(3) 2274(2) 3552(2) 32(1) 
C(10) 1522(2) 1256(2) 1106(2) 22(1) 
C(11) 1253(2) 2214(2) 967(2) 21(1) 
C(12) 616(3) 3352(2) -285(2) 31(1) 
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C(13) 1481(2) 1680(2) 5078(2) 28(1) 
C(14) 2714(3) 1514(2) 5429(2) 29(1) 
C(15) 4373(3) 1001(2) 6834(2) 38(1) 
P(1') 5318(1) -1214(1) 8917(1) 25(1) 
F(1') 4303(9) -1928(6) 8505(11) 66(3) 
F(2') 6311(9) -537(8) 9303(11) 57(3) 
F(3') 6146(9) -2005(6) 9423(7) 69(3) 
F(4') 5175(16) -1105(5) 9945(10) 103(4) 
F(5') 4431(8) -482(6) 8371(12) 79(4) 
F(6') 5445(13) -1393(8) 7869(7) 71(4) 
________________________________________________________________________________ 
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 Table 3.   Bond lengths [Å] and angles [°] for  trans-[RhCl2S4(COOCH3)2]PF6. 
_____________________________________________________  
Rh(1)-S(2)  2.3453(7) 
Rh(1)-Cl(1)  2.3459(7) 
Rh(1)-Cl(2)  2.3467(7) 
Rh(1)-S(3)  2.3545(7) 
Rh(1)-S(4)  2.3670(8) 
Rh(1)-S(1)  2.3716(7) 
S(1)-C(10)  1.811(2) 
S(1)-C(1)  1.815(3) 
S(2)-C(3)  1.816(3) 
S(2)-C(4)  1.820(3) 
S(3)-C(7)  1.817(3) 
S(3)-C(6)  1.821(3) 
S(4)-C(9)  1.810(3) 
S(4)-C(13)  1.812(3) 
P(1)-F(6)  1.568(7) 
P(1)-F(1)  1.570(8) 
P(1)-F(5)  1.570(7) 
P(1)-F(4)  1.587(5) 
P(1)-F(3)  1.605(6) 
P(1)-F(2)  1.622(6) 
O(1)-C(11)  1.199(3) 
O(2)-C(11)  1.342(3) 
O(2)-C(12)  1.463(3) 
O(3)-C(14)  1.202(3) 
O(4)-C(14)  1.342(3) 
O(4)-C(15)  1.449(3) 
C(1)-C(2)  1.525(4) 
C(1)-H(1A)  0.9900 
C(1)-H(1B)  0.9900 
C(2)-C(3)  1.520(4) 
C(2)-H(2A)  0.9900 
C(2)-H(2B)  0.9900 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
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C(4)-C(5)  1.521(4) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-C(6)  1.520(4) 
C(5)-H(5A)  0.9900 
C(5)-H(5B)  0.9900 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-C(8)  1.513(4) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(8)-C(9)  1.529(4) 
C(8)-H(8A)  0.9900 
C(8)-H(8B)  0.9900 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-C(11)  1.508(4) 
C(10)-H(10A)  0.9900 
C(10)-H(10B)  0.9900 
C(12)-H(12A)  0.9800 
C(12)-H(12B)  0.9800 
C(12)-H(12C)  0.9800 
C(13)-C(14)  1.502(4) 
C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 
C(15)-H(15A)  0.9800 
C(15)-H(15B)  0.9800 
C(15)-H(15C)  0.9800 
 
S(2)-Rh(1)-Cl(1) 88.42(3) 
S(2)-Rh(1)-Cl(2) 91.67(2) 
Cl(1)-Rh(1)-Cl(2) 178.36(2) 
S(2)-Rh(1)-S(3) 89.48(2) 
Cl(1)-Rh(1)-S(3) 91.47(3) 
Cl(2)-Rh(1)-S(3) 86.89(2) 
S(2)-Rh(1)-S(4) 173.52(2) 
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Cl(1)-Rh(1)-S(4) 86.51(3) 
Cl(2)-Rh(1)-S(4) 93.51(3) 
S(3)-Rh(1)-S(4) 94.67(3) 
S(2)-Rh(1)-S(1) 92.04(2) 
Cl(1)-Rh(1)-S(1) 92.38(3) 
Cl(2)-Rh(1)-S(1) 89.26(3) 
S(3)-Rh(1)-S(1) 175.90(2) 
S(4)-Rh(1)-S(1) 84.15(3) 
C(10)-S(1)-C(1) 99.67(12) 
C(10)-S(1)-Rh(1) 109.37(9) 
C(1)-S(1)-Rh(1) 109.39(9) 
C(3)-S(2)-C(4) 96.32(12) 
C(3)-S(2)-Rh(1) 110.63(9) 
C(4)-S(2)-Rh(1) 104.76(9) 
C(7)-S(3)-C(6) 97.29(13) 
C(7)-S(3)-Rh(1) 110.91(10) 
C(6)-S(3)-Rh(1) 105.01(9) 
C(9)-S(4)-C(13) 99.46(13) 
C(9)-S(4)-Rh(1) 109.70(10) 
C(13)-S(4)-Rh(1) 110.63(10) 
F(6)-P(1)-F(1) 91.3(5) 
F(6)-P(1)-F(5) 90.7(4) 
F(1)-P(1)-F(5) 93.4(5) 
F(6)-P(1)-F(4) 176.4(5) 
F(1)-P(1)-F(4) 92.2(3) 
F(5)-P(1)-F(4) 90.0(3) 
F(6)-P(1)-F(3) 90.1(4) 
F(1)-P(1)-F(3) 90.0(5) 
F(5)-P(1)-F(3) 176.5(5) 
F(4)-P(1)-F(3) 88.9(4) 
F(6)-P(1)-F(2) 89.4(6) 
F(1)-P(1)-F(2) 178.5(6) 
F(5)-P(1)-F(2) 87.9(5) 
F(4)-P(1)-F(2) 87.1(5) 
F(3)-P(1)-F(2) 88.7(5) 
C(11)-O(2)-C(12) 114.9(2) 
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C(14)-O(4)-C(15) 114.5(2) 
C(2)-C(1)-S(1) 117.64(18) 
C(2)-C(1)-H(1A) 107.9 
S(1)-C(1)-H(1A) 107.9 
C(2)-C(1)-H(1B) 107.9 
S(1)-C(1)-H(1B) 107.9 
H(1A)-C(1)-H(1B) 107.2 
C(3)-C(2)-C(1) 114.4(2) 
C(3)-C(2)-H(2A) 108.7 
C(1)-C(2)-H(2A) 108.7 
C(3)-C(2)-H(2B) 108.7 
C(1)-C(2)-H(2B) 108.7 
H(2A)-C(2)-H(2B) 107.6 
C(2)-C(3)-S(2) 114.12(18) 
C(2)-C(3)-H(3A) 108.7 
S(2)-C(3)-H(3A) 108.7 
C(2)-C(3)-H(3B) 108.7 
S(2)-C(3)-H(3B) 108.7 
H(3A)-C(3)-H(3B) 107.6 
C(5)-C(4)-S(2) 111.75(19) 
C(5)-C(4)-H(4A) 109.3 
S(2)-C(4)-H(4A) 109.3 
C(5)-C(4)-H(4B) 109.3 
S(2)-C(4)-H(4B) 109.3 
H(4A)-C(4)-H(4B) 107.9 
C(6)-C(5)-C(4) 114.6(2) 
C(6)-C(5)-H(5A) 108.6 
C(4)-C(5)-H(5A) 108.6 
C(6)-C(5)-H(5B) 108.6 
C(4)-C(5)-H(5B) 108.6 
H(5A)-C(5)-H(5B) 107.6 
C(5)-C(6)-S(3) 111.21(19) 
C(5)-C(6)-H(6A) 109.4 
S(3)-C(6)-H(6A) 109.4 
C(5)-C(6)-H(6B) 109.4 
S(3)-C(6)-H(6B) 109.4 
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H(6A)-C(6)-H(6B) 108.0 
C(8)-C(7)-S(3) 113.0(2) 
C(8)-C(7)-H(7A) 109.0 
S(3)-C(7)-H(7A) 109.0 
C(8)-C(7)-H(7B) 109.0 
S(3)-C(7)-H(7B) 109.0 
H(7A)-C(7)-H(7B) 107.8 
C(7)-C(8)-C(9) 113.7(2) 
C(7)-C(8)-H(8A) 108.8 
C(9)-C(8)-H(8A) 108.8 
C(7)-C(8)-H(8B) 108.8 
C(9)-C(8)-H(8B) 108.8 
H(8A)-C(8)-H(8B) 107.7 
C(8)-C(9)-S(4) 117.5(2) 
C(8)-C(9)-H(9A) 107.9 
S(4)-C(9)-H(9A) 107.9 
C(8)-C(9)-H(9B) 107.9 
S(4)-C(9)-H(9B) 107.9 
H(9A)-C(9)-H(9B) 107.2 
C(11)-C(10)-S(1) 109.76(18) 
C(11)-C(10)-H(10A) 109.7 
S(1)-C(10)-H(10A) 109.7 
C(11)-C(10)-H(10B) 109.7 
S(1)-C(10)-H(10B) 109.7 
H(10A)-C(10)-H(10B) 108.2 
O(1)-C(11)-O(2) 124.5(2) 
O(1)-C(11)-C(10) 125.9(2) 
O(2)-C(11)-C(10) 109.6(2) 
O(2)-C(12)-H(12A) 109.5 
O(2)-C(12)-H(12B) 109.5 
H(12A)-C(12)-H(12B) 109.5 
O(2)-C(12)-H(12C) 109.5 
H(12A)-C(12)-H(12C) 109.5 
H(12B)-C(12)-H(12C) 109.5 
C(14)-C(13)-S(4) 110.48(19) 
C(14)-C(13)-H(13A) 109.6 
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S(4)-C(13)-H(13A) 109.6 
C(14)-C(13)-H(13B) 109.6 
S(4)-C(13)-H(13B) 109.6 
H(13A)-C(13)-H(13B) 108.1 
O(3)-C(14)-O(4) 125.3(3) 
O(3)-C(14)-C(13) 125.2(3) 
O(4)-C(14)-C(13) 109.5(2) 
O(4)-C(15)-H(15A) 109.5 
O(4)-C(15)-H(15B) 109.5 
H(15A)-C(15)-H(15B) 109.5 
O(4)-C(15)-H(15C) 109.5 
H(15A)-C(15)-H(15C) 109.5 
H(15B)-C(15)-H(15C) 109.5 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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 Table 4.   Anisotropic displacement parameters  (Å2x 103) for trans-[RhCl2S4(COOCH3)2]PF6. The 
anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
Rh(1) 19(1)  19(1) 12(1)  0(1) 6(1)  0(1) 
Cl(1) 24(1)  27(1) 17(1)  5(1) 7(1)  4(1) 
Cl(2) 21(1)  23(1) 15(1)  2(1) 5(1)  0(1) 
S(1) 22(1)  27(1) 14(1)  1(1) 6(1)  -5(1) 
S(2) 18(1)  22(1) 16(1)  -1(1) 7(1)  0(1) 
S(3) 21(1)  24(1) 19(1)  2(1) 11(1)  3(1) 
S(4) 41(1)  20(1) 17(1)  -1(1) 13(1)  -1(1) 
P(1) 25(1)  27(1) 27(1)  7(1) 14(1)  2(1) 
F(1) 48(4)  51(5) 24(3)  -8(2) 18(2)  -25(3) 
F(2) 55(6)  21(3) 53(5)  -7(3) 39(4)  -18(3) 
F(3) 34(3)  25(3) 114(8)  -12(3) 39(4)  -2(2) 
F(4) 49(3)  43(3) 17(2)  5(2) -3(2)  -29(3) 
F(5) 21(2)  48(4) 46(4)  -20(3) 3(2)  8(2) 
F(6) 113(7)  37(3) 29(3)  -6(2) 39(4)  -13(4) 
O(1) 31(1)  25(1) 20(1)  -5(1) 11(1)  -5(1) 
O(2) 39(1)  18(1) 19(1)  0(1) 13(1)  -2(1) 
O(3) 41(1)  45(1) 24(1)  -8(1) 15(1)  -14(1) 
O(4) 32(1)  32(1) 20(1)  0(1) 10(1)  -3(1) 
C(1) 17(1)  37(2) 21(1)  8(1) 8(1)  1(1) 
C(2) 24(2)  30(2) 28(2)  5(1) 14(1)  8(1) 
C(3) 22(1)  23(1) 26(1)  3(1) 12(1)  6(1) 
C(4) 26(1)  21(1) 21(1)  -2(1) 12(1)  -3(1) 
C(5) 25(2)  32(2) 24(1)  -5(1) 9(1)  -9(1) 
C(6) 16(1)  35(2) 22(1)  -1(1) 7(1)  -4(1) 
C(7) 28(2)  35(2) 31(2)  7(1) 18(1)  14(1) 
C(8) 45(2)  33(2) 28(2)  5(1) 21(2)  17(1) 
C(9) 48(2)  24(2) 25(2)  3(1) 16(1)  14(1) 
C(10) 24(1)  28(2) 14(1)  1(1) 9(1)  -2(1) 
C(11) 18(1)  27(2) 18(1)  1(1) 8(1)  -5(1) 
C(12) 50(2)  19(1) 22(2)  3(1) 14(1)  -4(1) 
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C(13) 39(2)  28(2) 16(1)  -2(1) 11(1)  -1(1) 
C(14) 42(2)  21(2) 23(2)  -9(1) 13(1)  -10(1) 
C(15) 34(2)  43(2) 32(2)  1(2) 11(1)  -2(2) 
P(1') 25(1)  27(1) 27(1)  7(1) 14(1)  2(1) 
F(1') 39(4)  20(3) 156(9)  1(5) 60(6)  -5(3) 
F(2') 20(3)  87(7) 54(6)  -41(5) 7(3)  -7(4) 
F(3') 72(6)  71(5) 44(4)  3(3) 7(3)  43(4) 
F(4') 233(12)  43(3) 123(7)  7(5) 159(8)  11(6) 
F(5') 46(4)  28(4) 119(9)  27(5) -2(5)  5(3) 
F(6') 131(9)  65(7) 40(4)  -27(4) 59(5)  -68(6) 
______________________________________________________________________________ 
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 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for trans-[RhCl2S4(COOCH3)2]PF6. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1A) 3510 211 2429 30 
H(1B) 3155 -237 3247 30 
H(2A) 1870 -467 1034 31 
H(2B) 2870 -1112 1736 31 
H(3A) 1829 -1420 2737 28 
H(3B) 1295 -1806 1569 28 
H(4A) -263 -2116 2064 26 
H(4B) 15 -1488 3049 26 
H(5A) -2076 -1628 1197 33 
H(5B) -1871 -1782 2381 33 
H(6A) -2765 -486 1971 30 
H(6B) -2084 -163 1348 30 
H(7A) -2237 1228 2400 36 
H(7B) -2517 761 3261 36 
H(8A) -753 1407 4580 40 
H(8B) -1812 2042 4025 40 
H(9A) -411 2819 3965 39 
H(9B) -1042 2430 2805 39 
H(10A) 2111 1121 881 26 
H(10B) 838 916 660 26 
H(12A) 61 3546 -51 47 
H(12B) 316 3447 -1045 47 
H(12C) 1315 3684 85 47 
H(13A) 1389 2199 5446 34 
H(13B) 1142 1176 5264 34 
H(15A) 4471 529 6419 57 
H(15B) 4663 816 7570 57 
H(15C) 4789 1515 6795 57 
________________________________________________________________________________ 
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 Table 6.  Torsion angles [°]trans-[RhCl2S4(COOCH3)2]PF6. 
________________________________________________________________  
C(10)-S(1)-C(1)-C(2) -55.4(2) 
Rh(1)-S(1)-C(1)-C(2) 59.2(2) 
S(1)-C(1)-C(2)-C(3) -73.2(3) 
C(1)-C(2)-C(3)-S(2) 74.0(3) 
C(4)-S(2)-C(3)-C(2) -172.1(2) 
Rh(1)-S(2)-C(3)-C(2) -63.7(2) 
C(3)-S(2)-C(4)-C(5) -164.98(19) 
Rh(1)-S(2)-C(4)-C(5) 81.71(18) 
S(2)-C(4)-C(5)-C(6) -45.9(3) 
C(4)-C(5)-C(6)-S(3) -40.8(3) 
C(7)-S(3)-C(6)-C(5) -164.6(2) 
Rh(1)-S(3)-C(6)-C(5) 81.38(19) 
C(6)-S(3)-C(7)-C(8) -170.2(2) 
Rh(1)-S(3)-C(7)-C(8) -61.0(2) 
S(3)-C(7)-C(8)-C(9) 78.6(3) 
C(7)-C(8)-C(9)-S(4) -77.3(3) 
C(13)-S(4)-C(9)-C(8) -60.7(2) 
Rh(1)-S(4)-C(9)-C(8) 55.4(2) 
C(1)-S(1)-C(10)-C(11) -154.46(19) 
Rh(1)-S(1)-C(10)-C(11) 90.91(18) 
C(12)-O(2)-C(11)-O(1) 1.2(4) 
C(12)-O(2)-C(11)-C(10) -176.6(2) 
S(1)-C(10)-C(11)-O(1) 4.7(3) 
S(1)-C(10)-C(11)-O(2) -177.54(17) 
C(9)-S(4)-C(13)-C(14) -167.5(2) 
Rh(1)-S(4)-C(13)-C(14) 77.1(2) 
C(15)-O(4)-C(14)-O(3) -3.3(4) 
C(15)-O(4)-C(14)-C(13) 178.2(2) 
S(4)-C(13)-C(14)-O(3) 14.2(4) 
S(4)-C(13)-C(14)-O(4) -167.35(18) 
________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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 Table 7.  Least squares plane trans-[RhCl2S4(COOCH3)2]PF6. 
 
 Least-squares planes (x,y,z in crystal coordinates) and deviations from them 
 (* indicates atom used to define plane) 
 
  4.1338 (0.0026) x - 7.4697 (0.0029) y + 8.3869 (0.0027) z = 2.0966 (0.0008)  
 
 *    0.0953 (0.0003)  S1 
 *   -0.0915 (0.0003)  S2 
 *    0.0894 (0.0003)  S3 
 *   -0.0932 (0.0003)  S4 
      0.0125 (0.0004)  Rh1 
     -2.3331 (0.0008)  Cl1 
      2.3583 (0.0008)  Cl2 
 
 Rms deviation of fitted at 
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Appendix 5: LC-ESI-MS 
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